IntegraMed America, Inc. (Nasdaq:INMD), is a specialty health care services company offering products and services within emerging, niche medical sectors. Historically competing in the Fertility Care medical sector, in August of 2007 we acquired Vein Clinics of America ("VCA"). Vein Clinics of America has been dedicated exclusively to the treatment of varicose vein disease and is currently the largest medical group in the country dedicated to the treatment of all aspects of vein disease.
Our fertility network consists of over 100 infertility specialists in 30 major fertility centers throughout the United States, and our doctors perform approximately 20% of all In Vitro Fertilization (IVF) procedures in the U.S.
Vein Clinics of America operates 30 clinics in Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Missouri, North Carolina, Tennessee, Virginia and Wisconsin.
IntegraMed America, Inc. (Nasdaq:INMD), offers products and services to patients, providers, payors and pharmaceutical manufacturers focused on the $2 billion infertility industry. Specifically, the Company:
- Provides services to a network of leading Fertility Centers across the United States.
- Distributes pharmaceutical products and services directly to patients through IntegraMed Pharmaceutical Services, Inc.
Offers treatment financing programs to patients through IntegraMed Financial Services.
- Conducts infertility-related clinical research through the IntegraMed Research Institute
- Provides genetic testing services through IntegraMed
- Reproductive Genetics Institute.
Bay Area Women Sought for Egg Freezing Study
Reproductive Science Center of the San Francisco Bay research seeks couples with male factor infertility
SAN RAMON, CALIFORNIA (September 28, 2007) – Reproductive Science Center of the San Francisco Bay Area, in cooperation with ViaCell, Inc., has been awarded a research grant to evaluate the safety and effectiveness of ViaCyte, an investigational product intended to broaden reproductive options for women through freezing and thawing of human eggs (oocytes). RSC’s IVF and Medical Director Dr. Louis Weckstein is the principal clinical investigator.
The study seeks couples with male factor infertility who want to achieve pregnancy. Female participants must be healthy, between the ages of 21 and 35, and must not have had more than one previous miscarriage or more than one failed in vitro fertilization (IVF) attempt. The couple must be willing to undergo egg retrieval with an egg freeze and thaw, after which they will undergo intracytoplasmic sperm injection (ICSI) and embryo transfer in order to achieve pregnancy. Women enrolling in this study will have their procedures performed at RSC and should anticipate a time commitment of approximately 12-months (three to four months for a standard IVF cycle, cryopreservation and thaw of oocytes, embryo transfer, and up to nine months for the resulting pregnancy follow-up). There is no cost to any enrolled patients for their treatment in the course of this study.
Human oocyte cryopreservation or egg freezing has been investigated since the 1980's and has been used experimentally in certain IVF populations, in women who are undergoing cancer treatments who are at risk of losing their fertility, and in women choosing to preserve their fertility. There is currently no FDA-cleared product offered for oocyte cryopreservation. For more information regarding the study, please visit www.rscbayarea.com or call 925.973.5012.
|
